Tarceva
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated or dysregulated in many cancers, thereby leading to uncontrolled cell growth. In particular, EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer. Tarceva reversibly inhibits the kinase activity of EGFR, and has higher binding affinity for EGFR del19 or exon 21 point mutation L858R mutations compared with wild-type receptors. This prevents the initiation of signaling cascades and results in the inhibition of EGFR-dependent proliferation.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Tarceva : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
15 Figure 1: Tarceva for non-small cell lung cancer – SWOT analysis
16 Figure 2: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
17 Figure 3: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
19 Figure 4: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Tarceva drug profile
7 Table 2: Tarceva pivotal trial data in non-small cell lung cancer
10 Table 3: Tarceva ongoing late-phase clinical trials in non-small cell lung cancer
12 Table 4: Tarceva late-phase trial data in non-small cell lung cancer
20 Table 5: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
22 Table 6: Tarceva patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Capmatinib 
Sign up to the